Zoetis Q2 2026 Earnings Call Summary

1Key Financial Results and Metrics

Revenue: $2.5 billion, flat on a reported basis and down 1% on an organic operational basis.

Adjusted Net Income: $781 million, down 2% on an organic operational basis.

U.S. Revenue: $1.3 billion, down 7%, with Companion Animal revenue at $1.0 billion, down 11%.

Global Companion Animal Revenue: $1.7 billion, down 6%, with key Dermatology franchise at $395 million, down 16%.

Livestock Revenue: $731 million, up 11%, driven by strong demand in cattle and poultry.

Adjusted Diluted EPS: $1.87, up 4% year-over-year.

2Strategic Updates and Business Highlights

Market Dynamics: Companion Animal market facing pressure from declining veterinary clinic visits and increased price sensitivity among pet owners.

Leadership Changes: Abhay Nayak promoted to EVP and President of U.S. Commercial Operations; Jay Saccaro appointed as EVP, CFO, and COO to enhance decision-making and operational efficiency.

Product Innovations: Anticipated U.S. approval of long-acting Cytopoint to strengthen the Dermatology portfolio. Continued expansion of the diagnostics segment with the acquisition of VitalRADS and new product launches.

Cost Management: Focus on cost discipline and targeted investments to protect market share and drive long-term growth.

3Forward Guidance and Outlook

Revised Full-Year Guidance:

Organic operational revenue growth expected to decline 3% to 1%.

Adjusted net income anticipated to decline 9% to 5%.

Adjusted diluted EPS forecasted to be between $6.15 and $6.25.

Market Conditions: Continued pressure expected in Companion Animal segments, particularly Dermatology and parasiticides, with competitive and pricing pressures anticipated to persist.

4Bad News, Challenges, or Points of Concern

Declining Metrics: Significant declines in Companion Animal revenue, particularly in the U.S., with pressures from competitive discounting and reduced clinic visits.

Competitive Pressures: Increased competition in key therapeutic areas, particularly in Dermatology, leading to market share losses and necessitating aggressive promotional strategies.

Market Environment: Ongoing challenges with pet owner affordability affecting purchasing decisions, contributing to a more competitive landscape with discounting becoming a common strategy among competitors.

5Notable Q&A Insights

Pricing Strategy: Management emphasized a focus on gross-to-net pricing strategies rather than changing list prices, aiming to protect volume and market share amidst competitive pressures.

Promotional Duration: Promotions are expected to continue until market stabilization occurs, with the intensity of promotions varying by therapeutic area based on competitive dynamics.

Livestock Growth Expectations: While Q2 saw strong growth in Livestock, management indicated that future growth may moderate to mid- to high single-digit ranges, reflecting transitory factors in Q2 performance.

Leadership Stability: Questions regarding the balance of organizational stability amid leadership changes were addressed, with management expressing confidence in the current team’s ability to execute the strategy effectively. Overall, while Zoetis faces significant near-term challenges in the Companion Animal segment, particularly due to competitive pressures and changing market dynamics, the company remains committed to long-term growth through innovation and strategic management of its diverse portfolio.